Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.25 Analyst target: $27.87 Upside: 171.90%
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
See the full interactive analysis & chart →Informational only — not investment advice.